Effect of re-treatment with gefitinib (‘Iressa’, ZD1839) after acquisition of resistance

Publisher Website
Google Scholar
Abstract
A 70-year-old man with adenocarcinoma of the lung developed pulmonary metastases 7 months after middle and lower lobectomy of the right lung in October 1998. He received four courses of first-line chemotherapy with docetaxel/irinotecan from June to September 1999. The best response was stable disease and, after 6 months of treatment, there was evidence of progressive disease with increase in size and number of pulmonary metastases. Therefore, we recommended enrollment in a phase I study of gefitinib (‘Iressa’) [1], an orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.

This publication has 1 reference indexed in Scilit: